Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children

Several vaccines and extended half-life monoclonal antibodies (mAbs) against respiratory syncytial virus (RSV) have shown promise in clinical trials. We used age-structured transmission models to predict the possible impact of various RSV prevention strategies including maternal immunization, live-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhe, Weinberger, Daniel M., Pitzer, Virginia E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612629/
https://www.ncbi.nlm.nih.gov/pubmed/36302926
http://dx.doi.org/10.1038/s41541-022-00550-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612629/
https://www.ncbi.nlm.nih.gov/pubmed/36302926
http://dx.doi.org/10.1038/s41541-022-00550-5

Ejemplares similares